Table 1 Time to reach 2-fold or 5-fold of the starting volume for the five different tumour models and 4 different treatment arms
|  | Carrier | BIBW 2992 | 15f/15d + carrier | 15f/15d + BIBW 2992 |
|---|---|---|---|---|
A7 -Glioblastoma | ||||
GDV2(95% C.I.) | 6 d (6; 7) | 6.5 d (4; 8) | 16 d (7; 48) | 59.5 d (24; 65) |
ER/p-value | 1.08/1.00 | 3.72/0.01 | ||
GDV5(95% C.I.) | 12 d (11; 13) | 16 d (13; 21) | 56 d (53; 64) | 67 d (56; 72) |
ER/p-value | 1.33/0.01 | 1.20/0.02 | ||
FaDu–SCC from the head and neck | ||||
GDV2(95% C.I.) | 4 d (3; 5) | 51 d (35; 65) | 45 d (41; 48) | 49 d (40; 52) |
ER/p-value | 12.75/<0.0001 | 1.09/0.63 | ||
GDV5(95% C.I.) | 11.5 d (10; 16) | 90 d (55;112) | 54 d (47; 64) | 56 d (49; 63) |
ER/p-value | 7.83/<0.0001 | 1.04/0.87 | ||
UT-SCC-14 – SCC from the head and neck | ||||
GDV2(95% C.I.) | 7.5 d (6; 9) | n. a. | 50 d (41; 103) | 61 d (51; 85) |
ER/p-value | n. a. | 1.22/0.30 | ||
GDV5(95% C.I.) | 21 d (17; 26) | n. a. | 65 d (53; 122) | 91.5 d (79; 111) |
ER/p-value | n. a. | 1.41/0.15 | ||
A431–SCC from the cervix | ||||
GDV2(95% C.I.) | 4.5 d (4; 7) | n. a. | 38 d (5; 43) | 72 d (64; 84) |
ER/p-value | n. a. | 1.89/<0.0001 | ||
GDV5(95% C.I.) | 14.5 d (9; 15) | n. a. | 62.5 d (52; 66) | 122 d (64; 141) |
ER/p-value | n. a. | 1.95/0.0050 | ||
UT-SCC-15 –SCC from the head and neck | ||||
GDV2(95% C.I.) | 5 d (5; 8) | n. a. | 34 d (15; 42) | 56.5 d (48; 148) |
ER/p-value | n. a. | 1.66/0.03 | ||
GDV5(95% C.I.) | 16 d (14; 20) | n. a. | 50 d (43; 100) | 109 d (61; 182) |
ER/p-value | n. a. | 2.18/0.04 | ||